Physician profile
John E Vanmetre
NPI 1669474284
$1,375.11
in general payments reported to CMS, 2019-2025
26 companies · $80.53 in 2025
The $80.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.93 · 2020: $113 · 2021: $145 · 2022: $269 · 2023: $443 · 2024: $227 · 2025: $80.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $246.98 | 2023 | Nuplazid |
| Bayer Healthcare Pharmaceuticals INC. | $189.40 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $115.06 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $73.89 | 2020-2024 | Airsupra |
| Abbvie INC. | $71.28 | 2021 | |
| Pfizer INC. | $52.58 | 2021-2024 | |
| Shield Therapeutics INC | $51.85 | 2023-2024 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.59 | 2023-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $38.23 | 2022 | |
| Harmony Biosciences LLC | $37.72 | 2022 | |
| Novo Nordisk INC | $37.02 | 2019 | |
| Merck Sharp & Dohme LLC | $36.64 | 2022-2024 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $24.94 | 2022 | |
| Lilly USA, LLC | $20.82 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.62 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $18.93 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $18.76 | 2023 | Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $17.26 | 2019 | |
| Tactile Systems Technology INC | $16.91 | 2019 | |
| Medtronic, INC. | $15.21 | 2025 | Inceptiv |
| Teva Pharmaceuticals USA, INC. | $14.40 | 2023 | Austedo |
| Amgen INC. | $14.22 | 2024 | Tavneos |
| Paratek Pharmaceuticals, INC. | $12.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vanmetre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.